Objective
Design
Setting
Patients
Interventions
Main Outcome Measures
Results
Conclusions
Key Words
Materials and methods
Participants and Setting
Interview Procedure
Data Analysis
Results
Participant Characteristics
Characteristic | Gynecologists n = 10 | PCPs n = 8 |
---|---|---|
Specialty | ||
Internal medicine | — | 4 |
Family medicine | — | 3 |
Adolescent medicine | — | 1 |
Sex | ||
Male | 1 | 3 |
Female | 9 | 5 |
Years of experience after training | ||
<5 | 4 | 4 |
5–10 | 2 | 1 |
11–20 | 2 | 2 |
>20 | 2 | 1 |
Average number of patients provider diagnosed with PCOS in one month | ||
<1 | 3 | 2 |
1–2 | 4 | 2 |
3–9 | 2 | 3 |
>10 | 1 | 0 |
Thematic Analysis
Gynecologists | Primary care physicians |
---|---|
Diagnostic considerations | |
|
|
Screening for sequelae of PCOS | |
|
|
Treatment | |
|
|
|
|
| |
Long-term counseling | |
|
|
|
|
|
|
|
Diagnostic Considerations
Barriers
“I go to Uptodate to refresh myself and make sure I’m doing the right labwork—like the role of (luteinizing hormone) and (follicle-stimulating hormone) I always have to look up because it’s not at the top of my head … I didn’t want to skew myself so I purposely didn’t look (the criteria) up. It starts with an R. Rotterdam? That’s the one that comes to mind. I just run to Uptodate because I’m not doing this consistently. Can I look at them? I didn’t want to study for this (interview).” (PCP, practicing seven years)
“Rotterdam—it’s an adjustment. It’s not what I learned in med school, and that’s always a transition.” (PCP, practicing four years)
“I feel like there’s always controversy about how we diagnose PCOS, especially because right now, the diagnosis is clinical—you know, the hirsutism depends on ethnic group. Or oligo-ovulation can be from just obesity and not PCOS. Or people can have cysts on their ovaries just because. These are sort of soft criteria.” (PCP, practicing four years)
Facilitators
“I follow the Rotterdam criteria, which are oligomenorrhea, hyperandrogenism, and signs of (polycystic ovaries) on ultrasound. I document hirsutism and acne, but I nearly always send labs—TSH, prolactin, testosterone, ancillary labs would be A1c, HCG if no office urine. I do not always order an ultrasound if they fulfill those two.” (Gynecologist, practicing five years)
“I think it’s actually more helpful to use Rotterdam because you capture more women that this is affecting, especially if you don’t have an ultrasound to support it or you can’t get an ultrasound. I was taught that you needed all three in medical school.” (PCP, practicing four years)
Treatment of Symptoms of PCOS
Barriers
“Metabolic issues are difficult—I am not sure how much I should take on. I do not think I have the time/resources/knowledge to manage. I believe PCPs do a better job.” (Gynecologist, practicing 12 years)
“I am not clear on the benefit of metformin. I have consulted family medicine about metformin, and they also do not think it should be started. I wish I had better access to a nutritionist for PCOS.” (Gynecologist, practicing four years)
“(It’s) just the challenges I face with taking care of obese American patients. Diet, exercise, and the lack of good food resources. Not having somewhere to exercise or walk—all of the problems that plague the population I take care of.” (PCP, practicing four years)
“I think I would (refer to gynecology) … if they wanted an IUD (intrauterine device) or Nexplanon—something outside of practice.” (PCP, practicing three years)
“I do ask about menses in the annual, but many just come for sick visits and so we may not talk about their periods for a few years.” (PCP, practicing seven years)
“(Women with PCOS) need medications that I don’t really know how to navigate. Like sometimes metformin is used (for infertility), but I don’t have enough sophistication to know if they need certain doses or timing or when to pull it off. And I’ve never prescribed clomiphene.” (PCP, practicing 1.5 years)
Facilitators
“If they’re trying to get pregnant, then I take a careful menstrual history, tell them to track periods and send infertility labs. I might do a trial of letrozole up to three months depending on the situation.” (Gynecologist, practicing <1 year)
Screening for Long-Term Complications of PCOS
Barriers
“For women who have BMIs between 35 and 50—there’s other things we’re thinking about, maybe we’re not screening as much for their menses, and so we miss it in the context of the diabetes. I could imagine that I don’t do the best job to screen for that.” (PCP, practicing seven years)
Facilitators
“I do routine women’s health screening for their age. I’d pay attention to their diabetes screen and lipids—probably the same frequency as everyone else. But if the tests are abnormal, I’d check every year or so, maybe every 6 months if they’re getting close to a diagnosis.” (PCP, practicing three years)
Counseling on Long-Term Complications of PCOS
Barriers
“I find it difficult to find time to discuss lifestyle changes that are beneficial to their overall health.” (Gynecologist, practicing three years)
“Sometimes (my counseling) is over e-mail or through the patient portal … I do not bring people back for a discussion … I am completely booked in my patient schedule.”
“The biggest challenge is getting women to understand the longer-term risks when they don’t see themselves as having a problem. Like diabetes, cardiovascular disease, and fertility—trying to communicate that to younger women in their 20s is hard.” (PCP, practicing 11 years)
“The biggest challenge is when a patient isn’t trying to get pregnant. It is difficult to convince them to do something about it. Some women think ‘I only have six periods a year and I think that is fine’ but it is difficult to convince them they still need routine contraception and to potentially do more screening.” (Gynecologist, practicing <1 year)
“Definitely the longer-term risks (are challenging) because they require long follow-up. The other stuff is more immediate and pressing for the patient. They’re always bringing up these issues and so they get resolved. But the longer-term risks you have to continue to remember. When they have gaps in care or transition to a new provider, that diagnosis might be dropped because it falls to the wayside.” (PCP, practicing 11 years)
Facilitators
“I explain what it is and print something out for them to go home and read. Then if they have questions, we can follow-up.” (PCP, practicing 13 years)
Discussion
Conclusion
Supplementary data
- Supplemental Data 1
References
- The prevalence and features of the polycystic ovary syndrome in an unselected population.J Clin Endocrinol Metab. 2004; 89: 2745-2749
- Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.Fertil Steril. 2018; 110: 364-379
- Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2017; 102: 604-612
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril. 2004; 81: 19-25
- Diagnostic criteria for polycystic ovary syndrome: towards a rational approach.Blackwell Scientific Publications, Boston1992
- Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.J Clin Endocrinol Metab. 2006; 91: 4237-4245
- Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome.Fertil Steril. 2017; 107: 1380-1386.e1
- Knowledge of PCOS in physicians-in-training: identifying gaps and educational opportunities.Gynecol Endocrinol. 2020; 36: 854-859
- Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management.Clin Endocrinol (Oxf). 2005; 62: 289-295
- Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature.Arch Gynecol Obstet. 2012; 285: 689-697
- Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome.J Pediatr Adolesc Gynecol. 2015; 28: 43-46
- Polycystic ovary syndrome: perceptions and attitudes of women and primary health care physicians on features of PCOS and renaming the syndrome.J Clin Endocrinol Metab. 2014; 99: E107-E111
- Clinicians’ perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study.Hum Reprod. 2020; 35: 660-668
- Code saturation versus meaning saturation: how many interviews are enough?.Qual Health Res. 2017; 27: 591-608
- An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.Biometrics. 1977; 33: 363-374
- “Smart Forms” in an electronic medical record: documentation-based clinical decision support to improve disease management.J Am Med Inform Assoc. 2008; 15: 513-523
- Dietary management of women with polycystic ovary syndrome in the United Kingdom: the role of dietitians.J Hum Nutr Diet. 2009; 22: 551-558
- Personalized mobile tool AskPCOS delivering evidence-based quality information about polycystic ovary syndrome.Semin Reprod Med. 2018; 36: 66-72
- Knowledge and practices regarding polycystic ovary syndrome among physicians in Europe, North America, and internationally: an online questionnaire-based study.Semin Reprod Med. 2018; 36: 19-27
- Metabolic screening in patients with polycystic ovary syndrome is largely underutilized among obstetrician-gynecologists.Am J Obstet Gynecol. 2016; 215: 579.e1-579.e5
- The current description and future need for multidisciplinary PCOS clinics.J Clin Med. 2018; 7: 395
- Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.J Clin Endocrinol Metab. 2006; 91: 781-785
- Qualitative data analysis for health services research: developing taxonomy, themes, and theory.Health Serv Res. 2007; 42: 1758-1772
- Polycystic ovary syndrome in adolescents: a qualitative study.Psychol Res Behav Manag. 2019; 12: 715-723
- Welcome to implementation science.Implementation Sci. 2006; 1: 1
Article info
Publication history
Footnotes
I.T.-L.L. has nothing to disclose. S.S. has nothing to disclose. M.I. has nothing to disclose. T.C. has nothing to disclose. R.B. receives royalties from Oxford University Press, serves as a consultant for United Behavioral Health, and serves on the Clinical and Scientific Advisory Committee for Optum Behavioral Health. A.D. has nothing to disclose.
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- When expertise plus evidence-based medicine isn’t enough, will implementation science get us to the finish line?F&S ReportsVol. 3Issue 2
- PreviewEvidence-based medicine (EBM) is a term coined by Gordon Guyatt, Professor of Clinical Epidemiology and Biostatistics, McMaster University, in 1991 to describe a movement that had been building in the previous decades away from expert opinion and toward a more structured epistemological approach to evaluating, grading, and applying empirical evidence to the clinical practice of medicine (1). Over the 3 decades since its official birth, EBM has faced its share of criticism from scientists and clinicians for being overly prescriptive, inappropriately hierarchical, and out of touch with individual patient needs.
- Full-Text
- Preview